{"entity":{"id":"nct05502913","kind":"trial","name":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer","aka":[],"tldr":"A phase 2 trial in lung cancer, run by Soroka University Medical Center, now recruiting.","summary":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer is a phase 2, randomised interventional study registered as NCT05502913 by Soroka University Medical Center, with a registry enrolment figure of 80 participants, started 2023-09-01 and due to reach its primary completion in 2025-06-30. Interventions recorded: Antibiotics; FMT (Fecal Microbiota Transplantation). Conditions listed: Metastatic Lung Cancer. Primary outcome: Progression-free Survival (PFS). Sites: Israel. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05502913","url":"https://clinicaltrials.gov/study/NCT05502913"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05502913","phase":"2","setting":"Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Metastatic Lung Cancer","sponsor":"Soroka University Medical Center","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05502913/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}